A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Trial Profile

A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-LDL
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Mar 2017 Results of a pooled analysis from SPIRE-HR, SPIRE-LDL, SPIRE-LDL, SPIRE-LL, SPIRE-SI and SPIRE-AI studies (n=4449), published in the New England Journal of Medicine.
    • 01 Nov 2016 Results published in a Pfizer media release.
    • 01 Nov 2016 Primary endpoint has been met. (Percent Change from Baseline in LDL-C at Week 12), as reported in a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top